Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.
Female
Gestational Age
Humans
Infant, Extremely Premature
Infant, Newborn
Infusions, Intravenous
Insulin-Like Growth Factor Binding Protein 1
/ blood
Insulin-Like Growth Factor Binding Protein 3
/ therapeutic use
Insulin-Like Growth Factor I
/ deficiency
Interleukin-6
/ blood
Male
Randomized Controlled Trials as Topic
Recombinant Proteins
Retinopathy of Prematurity
/ prevention & control
IGF-1
IGFBP-1
IL-6
Inflammation
Preterm infants
rhIGF-1/rhIGFBP-3
Journal
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
04
07
2019
revised:
28
09
2019
accepted:
08
11
2019
pubmed:
23
11
2019
medline:
17
3
2021
entrez:
23
11
2019
Statut:
ppublish
Résumé
Steady state insulin-like growth factor-1 (IGF-1) levels vary significantly during continuous intravenous infusion of recombinant human insulin-like growth factor-1/recombinant human insulin-like growth factor binding protein-3 (rhIGF-1/rhIGFBP-3) in the first weeks of life in extremely preterm infants. We evaluated interleukin-6 (IL-6) and insulin-like growth factor binding protein-1 (IGFBP-1) levels as predictors of low IGF-1 levels. Nineteen extremely preterm infants were enrolled in a trial, 9 received rhIGF-1/rhIGFBP-3 and 10 received standard neonatal care. Blood samples were analyzed daily for IGF-1, IL-6 and IGFBP-1 during intervention with rhIGF-1/rhIGFBP-3. Thirty seven percent of IGF-1 values during active treatment were <20 μg/L. Among treated infants, higher levels of IL-6, one and two days before sampled IGF-1, were associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.30 (95% CI 1.03-1.63), p = .026, and 1.57 (95% CI 1.26-1.97), p < .001 respectively. Higher levels of IGFBP-1 one day before sampled IGF-1 was also associated with IGF-1 < 20 μg/L, gestational age adjusted OR 1.74 (95% CI 1.19-2.53), p = .004. In preterm infants receiving continuous infusion of rhIGF-1/rhIGFBP-3, higher levels of IL-6 and IGFBP-1 preceded lower levels of circulating IGF-1. These findings demonstrate a need to further evaluate if inflammation and/or infection suppress serum IGF-1 levels. The trial is registered at ClinicalTrials.gov (NCT01096784).
Identifiants
pubmed: 31756675
pii: S1096-6374(19)30054-1
doi: 10.1016/j.ghir.2019.11.001
pmc: PMC7054155
mid: NIHMS1069214
pii:
doi:
Substances chimiques
IGF1 protein, human
0
IGFBP1 protein, human
0
IL6 protein, human
0
Insulin-Like Growth Factor Binding Protein 1
0
Insulin-Like Growth Factor Binding Protein 3
0
Interleukin-6
0
Recombinant Proteins
0
Insulin-Like Growth Factor I
67763-96-6
Banques de données
ClinicalTrials.gov
['NCT01096784', 'NCT01096784']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : NEI NIH HHS
ID : R01 EY017017
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030904
Pays : United States
Organisme : NEI NIH HHS
ID : R24 EY024864
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090255
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest IH-P, DL and AH hold stock/stock options in Premalux AB, and have received consulting fees from Shire PLC. BH has received consulting fees from Premacure AB and Shire PLC, and grant/research support from Baxter. JB holds stock in Premalux AB.
Références
Acta Paediatr. 2016 Jun;105(6):576-86
pubmed: 26833743
J Clin Endocrinol Metab. 2002 Jul;87(7):3118-24
pubmed: 12107211
J Pediatr. 2019 Mar;206:56-65.e8
pubmed: 30471715
J Biol Chem. 2004 Feb 27;279(9):7438-46
pubmed: 14681231
Am J Perinatol. 2019 Dec;36(14):1442-1452
pubmed: 30685870
Pediatr Res. 2013 Nov;74(5):564-9
pubmed: 23942554
Pediatr Res. 2011 May;69(5 Pt 1):448-53
pubmed: 21263374
Curr Pharm Des. 2017;23(38):5964-5970
pubmed: 28969546
Pediatrics. 2003 Nov;112(5):1016-20
pubmed: 14595040
Proc Soc Exp Biol Med. 1997 Dec;216(3):319-57
pubmed: 9402139
Growth Horm IGF Res. 2017 Oct;36:44-51
pubmed: 28934640
Growth Horm IGF Res. 2018 Apr;39:19-24
pubmed: 29274846
Growth Horm IGF Res. 2013 Aug;23(4):98-104
pubmed: 23611528
J Clin Endocrinol Metab. 2002 May;87(5):2171-9
pubmed: 11994360
J Clin Invest. 1997 Feb 15;99(4):643-50
pubmed: 9045866
Acta Paediatr. 2013 Oct;102(10):e439-42
pubmed: 23819682
J Pediatr Endocrinol Metab. 2005 Aug;18(8):777-83
pubmed: 16200844
Growth Regul. 1992 Jun;2(2):69-79
pubmed: 1283100
Hum Reprod. 1998 May;13(5):1389-93
pubmed: 9647578
Endocrinology. 2000 Sep;141(9):3156-64
pubmed: 10965886
Endocrinology. 2001 Nov;142(11):4818-26
pubmed: 11606449
Biochem Biophys Res Commun. 1996 Nov 12;228(2):611-5
pubmed: 8920958
Brain Behav Immun. 2007 Oct;21(7):901-12
pubmed: 17475444
Pediatr Res. 2009 May;65(5):574-9
pubmed: 19190540
Endocrinology. 1991 Oct;129(4):2085-93
pubmed: 1915087
Growth Regul. 1994 Feb;4 Suppl 1:11-9
pubmed: 7515738
Cell Immunol. 2008 Mar-Apr;252(1-2):91-110
pubmed: 18325486
Eur J Endocrinol. 2006 Oct;155(4):567-74
pubmed: 16990656
Early Hum Dev. 1986 Feb;13(1):37-46
pubmed: 3956421
Pediatr Res. 2013 Jan;73(1):68-74
pubmed: 23095978
J Hypertens. 1997 Oct;15(10):1159-65
pubmed: 9350590
J Immunol. 2004 Jun 15;172(12):7272-81
pubmed: 15187102
Cytokine Growth Factor Rev. 2018 Feb;39:1-18
pubmed: 29398400
J Clin Endocrinol Metab. 2014 Jun;99(6):2128-37
pubmed: 24606092
Acta Paediatr. 2012 Dec;101(12):1211-6
pubmed: 22924869
PLoS One. 2014 Feb 18;9(2):e86928
pubmed: 24558364
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4711-4719
pubmed: 29131241
Acta Paediatr. 2007 Jun;96(6):830-6
pubmed: 17465986
Int J Mol Med. 2006 Dec;18(6):1011-8
pubmed: 17089003